#United Kingdom #Nottingham #Catalent #Codis

Codis Expands Its Spray Dry Network with Catalent Acquisition

In an exciting development for the pharmaceutical manufacturing sector, Codis, a prominent global contract development and manufacturing organization (CDMO) specializing in spray drying technologies, has finalized its acquisition of Catalent’s Nottingham facility in the UK. This strategic move is set to significantly enhance Codis' operational capabilities and offerings throughout Europe.

A New Chapter for Codis

The completion of this acquisition consolidates Codis’s position as a leader in the spray drying arena, allowing for a more comprehensive solution for clients seeking oral solid dose (OSD) formulations. With this facility now under their wing, Codis is poised to leverage the combined strengths of both locations—Nottingham and its existing operations in Haverhill—creating what can be described as Europe’s premier end-to-end spray dry capability. This integration not only encompasses development-stage spray drying but also includes advanced analytical services, clinical supply chains, and small-scale commercial manufacturing, all essential for efficient drug development processes.

Nicolas Fortin, CEO of Codis, expressed his enthusiasm about welcoming the Nottingham team: “This is an exciting milestone for Codis,” he stated. “Their scientific strength, development experience, and long track record of delivering high-quality spray-dried and oral solid dose solutions make them an exceptional addition to our organization.” The acquisition underscores Codis’s commitment to providing clients with a seamless pathway from development to commercial manufacturing.

Strengthening Market Position

Matt Streeter, who will lead the Nottingham facility as General Manager and join the Codis executive team, highlighted the excitement within the Nottingham team to integrate with Codis, emphasizing their ambitions to expand services significantly. This acquisition is particularly timely as Codis complements its existing large-scale commercial spray dryer facility in Haverhill, which is currently undergoing considerable upgrades to enhance its operational performance over the coming years.

The strategic merger of the Nottingham site with Codis's Haverhill location effectively sets the stage for an upgraded portfolio of bioavailability-enhancement solutions, allowing for a streamlined transition from early-stage development through clinical supplies to the creation of final oral dosage forms. As Steve Facer, Senior Vice President of Sales and Marketing at Codis, pointed out, the integration offers “something truly differentiated” in the market, making it a compelling option for customers dealing with poorly soluble molecules.

Looking Ahead

Codis is not just increasing its physical footprint in Europe; it is strategically enhancing its service offerings for the pharmaceutical, consumer health, nutraceutical, and other healthcare sectors. With state-of-the-art facilities spanning over 400,000 square feet across locations in the United States and the UK, Codis combines decades of regulatory experience and development expertise, ensuring their clients receive top-notch services that adhere to stringent industry standards.

The Nottingham facility's expertise in formulation and clinical supply, honed over two decades, will meld seamlessly with Codis's resources, enabling pharmaceutical companies to pursue innovative drug solutions effectively. This marks a significant step for Codis as it remains committed to delivering high-quality manufacturing solutions while exploring new frontiers in the industry.

In summary, the acquisition of Catalent’s Nottingham facility represents a pivotal development for Codis and its clients. As they journey forward, the integration of services and capabilities promises to empower pharmaceutical innovators while enhancing access to advanced manufacturing techniques that can address essential needs in drug formulation and delivery.